Melatonin
Sleep & Recovery

Melatonin

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone produced mainly by the pineal gland, with nighttime secretion regulated by light. As a supplement, it is studied primarily for circadian rhythm disorders (e.g. jet lag, shift work) and for some forms of insomnia, with effects that depend on dose, formulation, and timing relative to the sleep-wake cycle.

Endogenous hormone and supplement for circadian rhythm, sleep, and recovery

Melatonin

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone produced mainly by the pineal gland, with nighttime secretion regulated by light. As a supplement, it is studied primarily for circadian rhythm disorders (e.g. jet lag, shift work) and for some forms of insomnia, with effects that depend on dose, formulation, and timing relative to the sleep-wake cycle.

Mechanism of action

Agonism of MT1 and MT2 receptors (GPCRs) in the suprachiasmatic nucleus and other areas: MT1 promotes sleep onset by reducing the wakefulness signal, while MT2 contributes to circadian synchronization/phase shifting. It also modulates thermoregulation (reduction of core body temperature), the hypothalamic-pituitary-gonadal axis indirectly, and shows antioxidant/anti-inflammatory activity in experimental models (radical scavenging and regulation of antioxidant enzymes), with clinical relevance still undefined for many extra-sleep indications.

Supported benefits

  • Reduction of jet lag symptoms and improved adaptation to the new time zone (especially eastward travel) (strong)
  • Improved sleep onset latency and/or sleep quality in some forms of insomnia, with generally small but significant average effects in meta-analyses (moderate)
  • Circadian rhythm disorders (e.g. delayed phase, shift work sleep-wake disorder): support for realignment when used with appropriate timing and light hygiene (moderate)
  • Improved sleep in some specific populations (e.g. older adults; certain neuropsychiatric or neurodevelopmental conditions), with study heterogeneity (limited)
  • Effects on cardiometabolic, immune, or pain/inflammation parameters: preliminary and inconclusive results (emerging)

Safety & side effects

  • Daytime drowsiness, reduced alertness, slowed reaction times (risk for driving/operating machinery)
  • Headache, dizziness
  • Nausea or gastrointestinal disturbances
  • Vivid dreams/nightmares
  • Irritability or mood changes in susceptible individuals (rare but reported)
  • Possible transient worsening of sleep quality if timing/dose are not appropriate (e.g. taking it too late)

FAQ

Does melatonin “make you sleep” like a sleeping pill?

It acts primarily as a circadian signal (chronobiotic) and may facilitate falling asleep in some conditions, but it is not a classic sedative. The effect depends greatly on timing relative to the biological rhythm and light exposure.

Why does it sometimes not work or make sleep worse?

Common causes include timing not aligned with one’s circadian rhythm, exposure to bright light in the evening, a dose/formulation not suited to the goal (sleep onset vs sleep maintenance), or individual variability in metabolism.

Is it useful for jet lag?

The evidence is solid for reducing jet lag symptoms and facilitating adaptation, especially if taken close to the sleep time of the new time zone and combined with light management strategies.

Is there a risk of dependence or tolerance?

It is not typically associated with dependence like some hypnotics. However, repeated use can lead to “behavioral dependence” (psychological habit), and effectiveness may vary over time if circadian/environmental factors are not corrected.

What is the difference between immediate-release and extended-release?

Immediate-release rapidly increases levels and tends to be more geared toward sleep onset latency; extended-release aims to maintain more stable levels during the night, more similar to the physiological profile.

The information provided is for informational and educational purposes only. It does not constitute medical advice. Use must be evaluated and authorized by a qualified healthcare professional.

Mechanism of action

Agonism of MT1 and MT2 receptors (GPCRs) in the suprachiasmatic nucleus and other areas: MT1 promotes sleep onset by reducing the wakefulness signal, while MT2 contributes to circadian synchronization/phase shifting. It also modulates thermoregulation (reduction of core body temperature), the hypothalamic-pituitary-gonadal axis indirectly, and shows antioxidant/anti-inflammatory activity in experimental models (radical scavenging and regulation of antioxidant enzymes), with clinical relevance still undefined for many non-sleep indications.

Scientific benefits

Reduction of jet lag symptoms and improved adaptation to the new time zone (especially eastward travel)
Evidence level: strong
Improved sleep onset latency and/or sleep quality in some forms of insomnia, with generally small but significant average effects in meta-analyses
Evidence level: moderate
Circadian rhythm disorders (e.g. delayed sleep phase, shift work sleep-wake disorder): support for realignment when used with appropriate timing and light hygiene
Evidence level: moderate
Improved sleep in some specific populations (e.g. older adults; some neuropsychiatric or neurodevelopmental conditions) with heterogeneity across studies
Evidence level: limited
Effects on cardiometabolic, immune, or pain/inflammation parameters: preliminary and inconclusive results
Evidence level: emerging

Contraindications

  • Pregnancy and breastfeeding: insufficient safety data for non-medical use
  • Pediatric age: use only in selected clinical contexts and under supervision (specific risk/benefit profile)
  • Mood disorders (e.g. depression, bipolar disorder): caution due to possible effects on circadian rhythm and symptoms
  • Epilepsy or history of seizures: mixed evidence; requires clinical evaluation
  • Autoimmune diseases or immunomodulatory therapy: potential theoretical/clinical immune interaction to be assessed
  • Hepatic impairment: possible increased exposure due to reduced metabolism

Side effects

  • Daytime drowsiness, reduced alertness, slowed reaction time (risk for driving/operating machinery)
  • Headache, dizziness
  • Nausea or gastrointestinal disturbances
  • Vivid dreams/nightmares
  • Irritability or mood changes in susceptible individuals (rare but reported)
  • Possible transient worsening of sleep quality if timing/dose are not appropriate (e.g. taking it too late)

Interactions

  • Sedatives/hypnotics, alcohol, sedating antihistamines: increased sedation and psychomotor impairment
  • Anticoagulants/antiplatelet agents (e.g. warfarin): possible interactions and reported INR changes; clinical monitoring required
  • Drugs metabolized by or modulating CYP1A2: fluvoxamine (a strong inhibitor) can markedly increase melatonin levels; ciprofloxacin and some oral contraceptives may also increase exposure; smoking (an inducer) may reduce it
  • Antihypertensives: possible effects on blood pressure in some individuals; variable clinical relevance
  • Immunosuppressants: potential theoretical interference with immune modulation

Regulatory status

Heterogeneous regulation: in some countries it is a dietary supplement (with varying dose limits and claims), in others it is classified as a drug (often for extended-release formulations and specific indications). Rules on purity, dosage, and label claims depend on the jurisdiction.

Supplements and peptides

All supplements